Anzeige
Mehr »
Montag, 29.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Frankfurt
29.06.26 | 08:26
0,095 Euro
0,00 % 0,000
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0960,14122:59

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:59HOFSETH BIOCARE ASA: MANDATORY NOTIFICATION OF TRADE-
12:29HOFSETH BIOCARE ASA - VOTING UNDERTAKINGS SECURED IN RELATION TO PRIVATE PLACEMENT AND B-SHARE AMENDMENTS1
12:29HOFSETH BIOCARE ASA: DISCLOSURES OF LARGE SHAREHOLDINGS3
FrHOFSETH BIOCARE ASA: CONTEMPLATED PRIVATE PLACEMENT3
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
09.06.Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 20262
28.05.Hofseth BioCare ASA: Financial calendar1
22.05.Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M139Hofseth BioCare ASA ("HBC") has entered into an Exclusive License and Supply Agreement (the "Agreement") with Fission Holdings LLC ("Fission"), a US-based affiliate and sales channel operator headquartered...
► Artikel lesen
14.04.Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas284HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over...
► Artikel lesen
27.03.Hofseth BioCare ASA: HBC ANNUAL REPORT 20251
13.02.Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT759HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up...
► Artikel lesen
11.02.Hofseth Biocare ASA: Notification of major shareholdings2
07.11.25Hofseth Biocare ASA: Third Quarter 2025 Financial Report291HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting...
► Artikel lesen
28.10.25XFRA CAPITAL ADJUSTMENT INFORMATION - 28.10.2025415Das Instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY wird ex Kapitalmassnahme gehandelt am 28.10.2025 The instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY is traded ex capital adjustment...
► Artikel lesen
24.10.25Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio282NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
24.10.25Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio462NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
09.09.25Hofseth Biocare ASA: ProGo, the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways236HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
► Artikel lesen
22.08.25Hofseth Biocare ASA: Second Quarter 2025 Financial Report287HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1